Literature DB >> 24692519

Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B cell responses.

Gregg J Silverman1, Adam Pelzek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24692519      PMCID： PMC4386843          DOI： 10.3899/jrheum.140022

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  29 in total

1.  Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis.

Authors:  Laurence Menard; Jonathan Samuels; Yen-Shing Ng; Eric Meffre
Journal:  Arthritis Rheum       Date:  2011-05

2.  In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.

Authors:  Petra Roll; Khalid Muhammad; Mathias Schumann; Stefan Kleinert; Hermann Einsele; Thomas Dörner; Hans-Peter Tony
Journal:  Arthritis Rheum       Date:  2011-05

3.  B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy.

Authors:  Diego Catalán; Octavio Aravena; Francisca Sabugo; Pamela Wurmann; Lilian Soto; Alexis M Kalergis; Miguel Cuchacovich; Juan C Aguillón
Journal:  Arthritis Res Ther       Date:  2010-04-15       Impact factor: 5.156

4.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Authors:  Daniel J Wallace; William Stohl; Richard A Furie; Jeffrey R Lisse; James D McKay; Joan T Merrill; Michelle A Petri; Ellen M Ginzler; W Winn Chatham; W Joseph McCune; Vivian Fernandez; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

Review 5.  Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis.

Authors:  Gregg J Silverman; David L Boyle
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

6.  Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.

Authors:  Petra Roll; Thomas Dörner; Hans-Peter Tony
Journal:  Arthritis Rheum       Date:  2008-06

7.  Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.

Authors:  Magda Nakou; Georgios Katsikas; Prodromos Sidiropoulos; George Bertsias; Eva Papadimitraki; Amalia Raptopoulou; Helen Koutala; Helen A Papadaki; Herakles Kritikos; Dimitrios T Boumpas
Journal:  Arthritis Res Ther       Date:  2009-08-28       Impact factor: 5.156

8.  Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.

Authors:  M Margarida Souto-Carneiro; Vijayabhanu Mahadevan; Kazuki Takada; Ruth Fritsch-Stork; Toshihiro Nanki; Margaret Brown; Thomas A Fleisher; Mildred Wilson; Raphaela Goldbach-Mansky; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2009-06-05       Impact factor: 5.156

9.  Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).

Authors:  P Emery; P Durez; M Dougados; C W Legerton; J-C Becker; G Vratsanos; H K Genant; C Peterfy; P Mitra; S Overfield; K Qi; R Westhovens
Journal:  Ann Rheum Dis       Date:  2009-11-23       Impact factor: 19.103

10.  Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study.

Authors:  M H Buch; D L Boyle; S Rosengren; B Saleem; R J Reece; L A Rhodes; A Radjenovic; A English; H Tang; G Vratsanos; P O'Connor; G S Firestein; P Emery
Journal:  Ann Rheum Dis       Date:  2008-09-04       Impact factor: 19.103
View more
  3 in total

Review 1.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

2.  Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.

Authors:  Adam J Pelzek; Caroline Grönwall; Pamela Rosenthal; Jeffrey D Greenberg; Mandy McGeachy; Larry Moreland; William F C Rigby; Gregg J Silverman
Journal:  Arthritis Rheumatol       Date:  2017-05-03       Impact factor: 10.995

Review 3.  Personalized medicine in rheumatology: the paradigm of serum autoantibodies.

Authors:  Silvia Sirotti; Elena Generali; Angela Ceribelli; Natasa Isailovic; Maria De Santis; Carlo Selmi
Journal:  Auto Immun Highlights       Date:  2017-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.